Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Radionuclides of rare earth elements are gaining importance as emerging therapeutic agents in nuclear medicine. β ( - )-particle emitter (142)Pr [T (1/2) = 19.12 h, E (β) (-) = 2.162 MeV (96.3%), Eγ = 1575 keV (3.7%)] is one of the praseodymium-141 (100% abundant) radioisotopes. Production routes and therapy aspects of (142)Pr will be reviewed in this paper. However, (142)Pr produces via (141)Pr(n, γ)(142)Pr reaction by irradiation in a low-fluence reactor; (142)Pr cyclotron produced, could be achievable. (142)Pr due to its high β ( - )-emission and low specific gamma γ-emission could not only be a therapeutic radionuclide, but also a suitable radionuclide in order for biodistribution studies. Internal radiotherapy using (142)Pr can be classified into two sub-categories: (1) unsealed source therapy (UST), (2) brachytherapy. UST via (142)Pr-HA and (142)Pr-DTPA in order for radiosynovectomy have been proposed. In addition, (142)Pr Glass seeds and (142)Pr microspheres have been utilized for interstitial brachytherapy of prostate cancer and intraarterial brachytherapy of arteriovenous malformation, respectively.
Written by:
Bakht MK, Sadeghi M. Are you the author?
Reference: Ann Nucl Med. 2011 Jul 1. Epub ahead of print.
doi: 10.1007/s12149-011-0505-z
PubMed Abstract
PMID: 21720780
UroToday.com Prostate Cancer Section
